Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.23 -3.3%	$27.09	$20.84 ▼ $36.75	$2.50B	1.91	1.21 million shs	2.17 million shs
DNLI Denali Therapeutics	$15.15 +1.7%	$20.38	$14.01 ▼ $33.33	$2.20B	1.46	1.01 million shs	922,545 shs
NAMS NewAmsterdam Pharma	$23.37 -0.9%	$21.95	$15.19 ▼ $27.29	$2.57B	-0.04	487,946 shs	1.38 million shs
SANA Sana Biotechnology	$2.93 +10.6%	$3.03	$1.52 ▼ $10.50	$654.18M	1.63	2.98 million shs	2.99 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-3.31%	-14.92%	-15.19%	-13.25%	-35.16%
DNLI Denali Therapeutics	+1.75%	-9.23%	-27.23%	-34.04%	-27.51%
NAMS NewAmsterdam Pharma	-0.89%	-1.81%	+20.65%	-5.35%	+4.80%
SANA Sana Biotechnology	+10.57%	+13.57%	+3.17%	+55.03%	-70.25%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.1644 of 5 stars	4.5	1.0	0.0	2.5	2.5	0.6
DNLI Denali Therapeutics	4.1908 of 5 stars	4.5	1.0	4.7	1.8	2.5	0.0
NAMS NewAmsterdam Pharma	2.6311 of 5 stars	3.5	2.0	0.0	2.2	4.2	0.0
SANA Sana Biotechnology	3.1405 of 5 stars	3.4	3.0	0.0	2.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$50.82	109.73% Upside
DNLI Denali Therapeutics	2.94	Moderate Buy	$37.20	145.54% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.33	85.42% Upside
SANA Sana Biotechnology	2.83	Moderate Buy	$12.25	318.09% Upside

Current Analyst Ratings Breakdown

Latest SANA, DNLI, BEAM, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/14/2025	SANA Sana Biotechnology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/10/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $28.00
3/7/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00 ➝ $33.00
3/5/2025	DNLI Denali Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $35.00
3/3/2025	NAMS NewAmsterdam Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$41.00
3/3/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $25.00

(Data available from 3/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	38.06	N/A	N/A	$12.04 per share	2.01
DNLI Denali Therapeutics	$330.53M	6.66	N/A	N/A	$7.42 per share	2.04
NAMS NewAmsterdam Pharma	$45.56M	56.33	N/A	N/A	$3.50 per share	6.68
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.57	N/A	N/A	N/A	N/A	-32.94%	-30.04%	5/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$2.60	N/A	N/A	N/A	N/A	N/A	N/A	5/14/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$1.40	N/A	N/A	N/A	N/A	-84.22%	-44.97%	3/20/2025 (Estimated)

Latest SANA, DNLI, BEAM, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2025	N/A	SANA Sana Biotechnology	-$0.22	N/A	N/A	N/A	N/A	N/A
2/27/2025	Q4 2024	DNLI Denali Therapeutics	-$0.75	-$0.67	+$0.08	-$0.67	$12.75 million	N/A
2/26/2025	Q4 2024	NAMS NewAmsterdam Pharma	-$0.48	-$0.95	-$0.47	-$0.95	$3.30 million	$12.77 million
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.71%	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
DNLI Denali Therapeutics	N/A	9.98	9.98
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
NAMS NewAmsterdam Pharma	89.89%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
DNLI Denali Therapeutics	7.90%
NAMS NewAmsterdam Pharma	19.50%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	99.79 million	79.33 million	Optionable
DNLI Denali Therapeutics	430	145.22 million	132.55 million	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
SANA Sana Biotechnology	380	223.27 million	153.83 million	Optionable

SANA, DNLI, BEAM, and NAMS Headlines

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Shares Gap Up - Still a Buy?

March 15 at 12:33 PM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

March 15 at 8:31 AM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Earns Buy Rating from Analysts at Jefferies Financial Group

March 15 at 8:09 AM | marketbeat.com

Jefferies Initiates Coverage of Sana Biotechnology (SANA) with Buy Recommendation

March 15 at 7:57 AM | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 8.7% - What's Next?

March 14 at 4:28 PM | marketbeat.com

Sana Biotechnology initiated with a Buy at Jefferies

March 14 at 9:18 AM | markets.businessinsider.com

Analyzing Scilex (NASDAQ:SCLX) and Sana Biotechnology (NASDAQ:SANA)

March 14 at 2:09 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Beam Therapeutics (BEAM)

March 13 at 5:44 AM | markets.businessinsider.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 9.7% - What's Next?

March 12 at 6:18 PM | marketbeat.com

Sana Biotechnology options imply 6.3% move in share price post-earnings

March 7, 2025 | markets.businessinsider.com

Is Sana Biotechnology (SANA) Among Jeff Bezos’ Investments in 2025?

March 4, 2025 | insidermonkey.com

Sana Biotechnology (SANA) Expected to Announce Earnings on Thursday

March 4, 2025 | marketbeat.com

Why Sana Biotechnology, Inc. (SANA) is Skyrocketing So Far in 2025

March 1, 2025 | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Trading 6.3% Higher - Still a Buy?

February 28, 2025 | marketbeat.com

Sana Biotechnology (SANA) to Release Quarterly Earnings on Thursday

February 27, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 8.9% - Should You Sell?

February 25, 2025 | marketbeat.com

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

February 24, 2025 | globenewswire.com

Sana Biotechnology, Inc. (SANA)

February 23, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 9.8% - Here's What Happened

February 15, 2025 | marketbeat.com

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

January 31, 2025 | msn.com

What’s Behind the -4.69% Drop in Sana Biotechnology Inc (SANA) Stock? Find Out Now!

January 31, 2025 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, DNLI, BEAM, and NAMS Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.23 -0.83 (-3.31%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$24.33 +0.10 (+0.41%)

As of 03/14/2025 07:56 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.15 +0.26 (+1.75%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$15.14 -0.01 (-0.03%)

As of 03/14/2025 07:14 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

NewAmsterdam Pharma NASDAQ:NAMS

$23.37 -0.21 (-0.89%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$23.38 +0.01 (+0.04%)

As of 03/14/2025 04:05 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sana Biotechnology NASDAQ:SANA

$2.93 +0.28 (+10.57%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$2.80 -0.13 (-4.47%)

As of 03/14/2025 07:59 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time